OpportunityTitle: Cancer Immunoprevention Network (CIP-Net) ?Research Projects (UG3/UH3 Clinical Trials Not Allowed)
AdditionalInformationOnEligibility: Other Eligible Applicants include the following:  Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.  Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.  Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Description: The purpose of the Cancer Immunoprevention Network (CIP-Net) is to support a deeper understanding of basic mechanisms of immunoprevention, discover novel immunoprevention strategies, and foster a community of cancer immunoprevention researchers. ?The UG3/UH3 research projects will enable de novo discovery of immune pathways, immunoprevention mechanisms, or investigation of new vaccine or immunomodulatory targets or agents. Applicants responding to this FOA must apply for both the UG3 and UH3 phases together in a single application. Achievement of the UG3 milestones will be necessary for transition to the UH3 phase. UH3 phase may be awarded after administrative review of the UG3 milestones. Provided these milestones are achieved, UH3 phase may continue.
GrantorContactEmailDescription: See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
GrantorContactText: NIH Grants Information&lt;br/&gt;grantsinfo@nih.gov